Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA) will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, March 8-11, 2026, in Orlando, Florida.

Presentations include 1-year Phase 1/2 EXPLORE44 del-zota data showing near normalization of creatine kinase and functional improvements in DMD44, multiple DM1 and FSHD studies, and the SAFARI44 Phase 3 design. Materials will be posted on the company publications page after the meeting.

Market Reaction – RNA

-4.61% $14.07

15m delay 2 alerts

-4.61% Since News

-3.1% Trough Tracked

$14.07 Last Price

$13.06 $15.93 Day Range

0.0x Rel. Volume

Following this news, RNA has declined 4.61%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $14.07.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Oral presentations: 1 oral presentation Poster presentations: 6 poster presentations Conference dates: March 8–11, 2026 +2 more

5 metrics

Oral presentations 1 oral presentation Company presentations at 2026 MDA Clinical & Scientific Conference

Poster presentations 6 poster presentations Company presentations at 2026 MDA Clinical & Scientific Conference

Conference dates March 8–11, 2026 2026 MDA Clinical & Scientific Conference schedule

Del-zota data horizon 1-year data Phase 1/2 EXPLORE44 program in DMD44

Industry lunch date March 10, 2026 Avidity-sponsored industry forum lunch during MDA conference

Market Reality Check

Price: $72.80 Vol: Volume 11,631,072 is 3.32...

high vol

$72.80 Last Close

Volume Volume 11,631,072 is 3.32x the 20-day average of 3,498,813, indicating elevated interest ahead of the conference. high

Technical Price $72.80 is trading above the 200-day MA at $52.46 and is near the 52-week high of $73.06.

Peers on Argus

RNA shows a slight positive move of 0.07% while key biotech peers like CRSP (-4....

1 Down

RNA shows a slight positive move of 0.07% while key biotech peers like CRSP (-4.12%), PTCT (-1.67%), TGTX (-2.08%), MRUS (-7.08%) and NUVL (-0.46%) are down, suggesting stock-specific dynamics.

Common Catalyst Several peers (TGTX, NUVL) reported earnings-related updates, while RNA’s news focuses on upcoming clinical conference presentations.

Historical Context

5 past events · Latest: Feb 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Special meeting adjournment	Neutral	+0.1%	Adjusted special meeting timing to meet conditions for SpinCo distribution and merger.
Feb 18	Clinical data publication	Positive	+0.0%	Phase 1/2 MARINA NEJM publication showing clinical benefit and acceptable safety in DM1.
Feb 02	Spin-off record date	Positive	+0.3%	Set record date for pro rata SpinCo share distribution tied to Novartis acquisition.
Nov 19	Managed Access Program	Positive	+0.1%	Announced U.S. MAP for del-zota in DMD44 with planned 2026 BLA submission.
Nov 19	Housing project launch	Neutral	+0.1%	Toll Brothers announced a new housing community; unrelated but recorded in history feed.

Pattern Detected

Recent RNA news — including spin-off mechanics, clinical data, and access programs — has generally been followed by modestly positive price reactions, indicating a pattern of constructive responses across different catalyst types.

Recent Company History

Over the past six months, RNA has combined corporate and clinical milestones with steady market support. Spin-off and merger mechanics were detailed on Feb 2, 2026 and reiterated on Feb 23, 2026, both followed by small gains. Clinical visibility increased with NEJM Phase 1/2 MARINA data for del-desiran on Feb 18, 2026 and a del-zota Managed Access Program announcement on Nov 19, 2025, each aligning with modest positive moves. Today’s MDA conference presentation plan extends this pattern of frequent clinical communication.

Market Pulse Summary

This announcement outlines RNA’s scientific presence at the 2026 MDA conference, including 1 oral an...

Analysis

This announcement outlines RNA’s scientific presence at the 2026 MDA conference, including 1 oral and 6 poster presentations featuring 1-year EXPLORE44 del-zota data and broader neuromuscular disease work. It extends a recent cadence of visibility that includes NEJM-published MARINA results and a del-zota access program. Investors may watch for detailed efficacy, biomarker, and functional outcome data from these sessions, alongside ongoing merger and spin-off developments disclosed in recent filings.

Key Terms

antibody oligonucleotide conjugates, duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, +4 more

8 terms

antibody oligonucleotide conjugates medical

"a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™)"

A therapy made by chemically attaching a short strand of genetic material (an oligonucleotide) to an antibody so the antibody can carry that genetic payload directly to specific cells. Think of the antibody as a guided delivery vehicle and the oligonucleotide as a small instruction manual that can turn genes on or off. Investors care because this approach aims to increase effectiveness and reduce side effects, but it also raises development complexity, regulatory scrutiny, and potential for high reward if clinically successful.

duchenne muscular dystrophy medical

"people living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44)"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

myotonic dystrophy type 1 medical

"Patient Journey Among Individuals with Myotonic Dystrophy Type 1 (DM1)"

A genetic, progressive disorder that causes muscle stiffness, weakness and a range of problems in other body systems (such as breathing, heart rhythm, vision and cognition); symptoms can vary widely and often worsen over time. For investors, it matters because its chronic, multisystem nature shapes the size of the potential patient population, the complexity and cost of clinical trials, regulatory requirements, and long-term demand for any effective treatments — think of it as a condition that requires multiple pieces to be fixed, not just a single part.

facioscapulohumeral muscular dystrophy medical

"Humanistic Burden of Facioscapulohumeral Muscular Dystrophy: Evidence from a Systematic"

A genetic progressive muscle disorder that slowly weakens the face, shoulder blades and upper arms, often making everyday actions like smiling, lifting objects or raising the arms harder over time. Investors care because it represents a clear unmet medical need: treatments or tests that slow progression, restore function, or improve diagnosis can command significant demand and regulatory attention, similar to developing a new fix for a widespread, uncontrolled mechanical fault in a critical system.

creatine kinase medical

"including near normalization of creatine kinase levels and improvements in functional"

An enzyme found mainly in heart, brain and skeletal muscle that appears in the bloodstream when those tissues are damaged; higher blood levels of creatine kinase act like a leak detector indicating injury such as a heart attack, muscle disease, or drug-related toxicity. Investors care because creatine kinase is a common safety and diagnostic marker used in clinical trials, regulatory reports and medical testing, and unexpected changes can affect a drug’s development, approval prospects or a diagnostics company’s performance.

rnaseq medical

"Delpacibart zotadirsen Improves Inflammatory and Fibrotic Disease Signatures ...: RNASeq Analysis"

RNA sequencing (rnaseq) is a laboratory method that reads and counts the active genetic messages cells are using, like scanning a recipe book to see which dishes are being cooked. Investors care because it reveals which genes are involved in diseases, helps identify drug targets and biomarkers, and supports diagnostic tests and clinical trial decisions; improvements in speed, cost, or accuracy can materially affect the value of biotech and diagnostics companies.

phase 1/2 medical

"1-year del-zota data from Avidity's Phase 1/2 EXPLORE44 program including near"

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

phase 3 medical

"SAFARI44: Design of a Phase 3 Global Study to Evaluate the Efficacy and Safety"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida.

2026 MDA Clinical & Scientific Congress Presentations

Oral Presentation: Del-zota Treatment is Associated with Near Normalization of CK Levels and Improvements in Key Functional Outcomes at 1 Year in Participants with DMD44 (March 11, 2026: 12:30 p.m. – 12:45 p.m. ET)

• Craig McDonald, M.D., Professor and Chair of the Departments of Physical Medicine and Rehabilitation and Director of the Neuromuscular Disease Clinic at the University of California, Davis, will present 1-year del-zota data from Avidity's Phase 1/2 EXPLORE44 program including near normalization of creatine kinase levels and improvements in functional outcomes in people living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44).

Poster Presentations

• #138 M: Patient Journey Among Individuals with Myotonic Dystrophy Type 1 (DM1): a Patient and Caregiver Interview Study (March 9, 2026)
• #129 M: Experiences with Myotonic Dystrophy Type 1 (DM1) and Treatment with Del-desiran: Interviews with Participants in MARINA-OLE and their Caregivers (March 9, 2026)
• #313 T: DUX4 Drives Delayed and Concordant Downstream Regulation of KHDC1L in FSHD Cell Line Models (March 10, 2026)
• #303 T: Humanistic Burden of Facioscapulohumeral Muscular Dystrophy: Evidence from a Systematic Literature Review (March 10, 2026)
• #165 M: SAFARI44: Design of a Phase 3 Global Study to Evaluate the Efficacy and Safety of delpacibart zotadirsen (del-zota; AOC 1044) in Treating DMD44 (March 9, 2026)
• #53 S: Delpacibart zotadirsen Improves Inflammatory and Fibrotic Disease Signatures in DMD44 Muscle: RNASeq Analysis in the EXPLORE44 Trial (March 8, 2026)

The presentation and posters will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com following the conference.

Avidity Sponsored Industry Forum Lunch Event During MDA Conference

On March 10, 2026, from 12:00 p.m. – 1:30 p.m. ET, in room Key West ABCD at the Hilton Orlando, Avidity will host an industry forum lunch titled "Biomarker Advancements in Rare Neuromuscular Disease: Insights from DMD and FSHD."

The event will feature guest speakers Aravindhan Veerapandiyan, M.D., Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, and Stephen Tapscott, M.D, Ph.D., Professor of Human Biology and Clinical Research, Fred Hutchinson Cancer Center. Participation will be open to all MDA Conference registered attendees.

About Avidity  
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Media Contact:
Kristina Coppola
(619) 837-5016
media@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-multiple-upcoming-presentations-at-2026-muscular-dystrophy-association-mda-clinical--scientific-conference-302698997.html

SOURCE Avidity Biosciences, Inc.

FAQ

What data will Avidity Biosciences (RNA) present on del-zota at the MDA conference on March 11, 2026?

Avidity will present 1-year EXPLORE44 del-zota data showing near normalization of creatine kinase and improved functional outcomes. According to Avidity, Craig McDonald, M.D., will present these DMD44 results on March 11, 2026 at 12:30 p.m. ET.

Which Avidity (RNA) poster covers the Phase 3 SAFARI44 study design and when is it presented?

The SAFARI44 Phase 3 study design poster is scheduled for March 9, 2026. According to Avidity, poster #165 M details the global trial design evaluating delpacibart zotadirsen efficacy and safety for DMD44.

How can investors access Avidity (RNA) presentations and posters after the March 2026 MDA conference?

Presentations and posters will be posted on Avidity's publications page following the conference. According to Avidity, materials from March 8-11, 2026 will be available on the company website after the event concludes.

What topics will Avidity (RNA) cover at its March 10, 2026 industry forum lunch during the MDA conference?

Avidity's industry forum will focus on biomarker advancements in rare neuromuscular disease, with DMD and FSHD insights. According to Avidity, the event runs March 10, 2026, 12:00–1:30 p.m. ET at Hilton Orlando and is open to registered attendees.

Which Avidity (RNA) posters at MDA 2026 address myotonic dystrophy type 1 (DM1) and when are they presented?

Two DM1-focused posters are scheduled for March 9, 2026 addressing patient journeys and del-desiran treatment experiences. According to Avidity, posters #138 M and #129 M report patient and caregiver interview study findings from MARINA-OLE participants.

Does Avidity (RNA) present research on FSHD at the March 2026 MDA conference and which poster covers molecular findings?

Yes, Avidity will present FSHD research including molecular regulation and humanistic burden analyses. According to Avidity, poster #313 T covers DUX4-driven KHDC1L regulation and poster #303 T reviews humanistic burden evidence on March 10, 2026.